In future studies, we can screen drug-resistant organoid strains in our laboratory’s colon cancer organoid bank, and try to combine NCT-503 or CBR-5884 with various chemotherapy regimens to explore new strategies of PHGDH inhibitors in the treatment of colon cancer. Here, PHGDH is linked to malignant colon neoplasm.